Xilio Therapeutics (XLO) Other Non-Current Liabilities (2020 - 2026)

Xilio Therapeutics has disclosed Other Non-Current Liabilities across 6 years of filings, most recently posting $26.3 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $26.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $26.3 million (changed N/A YoY), and the FY2025 annual result was $29.6 million, changed N/A from the prior year.
• Other Non-Current Liabilities came in at $26.3 million for Q1 2026 at Xilio Therapeutics, down from $29.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $53.9 million in Q3 2025 to a low of $7000.0 in Q2 2023.
• The 4-year median for Other Non-Current Liabilities is $91000.0 (2022), against an average of $14.9 million.
• Peak annual rise in Other Non-Current Liabilities reached 61.86% in 2022, while the deepest fall reached 95.8% in 2022.
• Xilio Therapeutics' Other Non-Current Liabilities stood at $45000.0 in 2022, then sank by 84.44% to $7000.0 in 2023, then surged by 422185.71% to $29.6 million in 2025, then fell by 11.16% to $26.3 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $26.3 million (Q1 2026), $29.6 million (Q4 2025), and $53.9 million (Q3 2025), per Business Quant data.